Skip to main navigation
Skip to search
Skip to main content
The University of Brighton Home
Home
Profiles
Research units
Equipment
Projects
Research output
Activities
Student theses
Search by expertise, name or affiliation
Emerging drugs for renal failure
P.K. Chatterjee, C. Thiemermann
University of Brighton
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Emerging drugs for renal failure'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Emerging Drugs
100%
Renal Failure
100%
Chronic Kidney Disease
83%
End-stage Renal Failure
50%
Renal Replacement Therapy
50%
Acute Renal Failure
33%
End-stage Renal Disease
33%
Teamwork
16%
Kidney
16%
Renal Transplantation
16%
Erythropoietin
16%
Beneficial Effects
16%
Clinical Setting
16%
Dialysis
16%
Risk Factors
16%
Expert Team
16%
Calcitriol
16%
Essential Function
16%
Angiotensin-converting Enzyme Inhibitor (ACEi)
16%
Sudden Onset
16%
Specialized Units
16%
Low-dose Dopamine
16%
Renal Inflammation
16%
Atrial Natriuretic Peptide
16%
Statins
16%
Pharmacological Intervention
16%
Rapid Onset
16%
Medicine and Dentistry
Renal Failure
100%
End Stage Renal Disease
83%
Chronic Kidney Disease
83%
Renal Replacement Therapy
50%
Acute Kidney Injury
33%
Low Drug Dose
16%
Kidney Transplantation
16%
Statin
16%
ACE Inhibitor
16%
Erythropoietin
16%
Atrial Natriuretic Factor
16%
Nephritic Syndrome
16%
Calcitriol
16%
Pharmacology, Toxicology and Pharmaceutical Science
Kidney Failure
100%
End Stage Renal Disease
83%
Chronic Kidney Failure
83%
Replacement Therapy
50%
Acute Kidney Failure
33%
Erythropoietin
16%
Dipeptidyl Carboxypeptidase Inhibitor
16%
Calcitriol
16%
Atrial Natriuretic Factor
16%
Nephritis
16%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
16%